Cookies on this site

Many congratulations to Associate Professor Carlo Rinaldi and Senior Postdoctoral Scientist Antonio Garcia-Guerra, who have been awarded the Novartis Global Scholar Program (NGSP) for 2023.

Associate Professor Carlo Rinaldi (right) and Senior Postdoctoral Scientist Antonio Garcia-Guerra (left)

NGSP offers innovators from selected world-class institutions funding for breakthrough scientific projects, addressing major bottlenecks in different areas of medicine and whose resolution would positively impact patients worldwide. Through this program, Novartis Biomedical Research supports projects focused on novel science with the objective of being translated to drug discovery and/or clinical research. Academic scholars have access to disease biology, drug-hunting and translational research expertise and each selected scholar will join forces with other entrepreneurially motivated Novartis Biomedical Research scientists to challenge the status quo and take bold risks for potential big rewards. They will also have an opportunity to advance research into early development stages. 

Combining complementary expertise in molecular mechanisms of disease and synthetic biology and nucleic acid delivery, team lead and NGSP Scholar, Carlo Rinaldi, and NGSP Co-Investigator, Antonio García-Guerra, will use the award to develop an innovative cell and tissue-specific gene editing approach in preclinical models of neuromuscular diseases. 

In a joint statement, Carlo and Antonio commented: “We are incredibly grateful to Novartis for this award. This type of research can have an enormous positive impact, and is only made possible through the unique combination of the University of Oxford ecosystem, Novartis translational research expertise and the ingenuity of the scientists involved.”

Similar stories

New $46M Grant Allows the University of Oxford and Boston Children’s Hospital to Lead Genetic Medicines Hub within ARIA Ecosystem

The University of Oxford and Boston Children’s Hospital, with collaboration from The Jackson Laboratory and N=1 Collaborative, have been selected to establish a new Genetic Medicines Hub, one of six research hubs within the Aligning Research to Impact Autism (ARIA) ecosystem.

Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.

University of Oxford and BIIE launch collaboration in translational immune engineering

Researchers from the Department of Paediatrics at the University of Oxford and the Botnar Institute of Immune Engineering (BIIE) came together in Oxford last week for the inaugural scientific meeting of the new Basel–Oxford Centre for Translational Immune Engineering for Child and Adolescent Health (CTIE). The CTIE is a new collaboration between the Department of Paediatrics and the BIIE in Basel, Switzerland, designed to accelerate the translation of advances in immune engineering into new diagnostics, vaccines, therapeutics and other approaches to prevent and treat disease. Its focus is on improving the health of children and adolescents in low- and middle-income countries.

Oxford-led newborn screening pilot expanded to include all babies in England

Every newborn baby in England will be screened for spinal muscular atrophy (SMA), following the expansion of a pioneering University of Oxford-led pilot that introduced the country’s first routine test for the condition.

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Oxford University and King’s College London Join IMPACT Network Study to Advance Understanding of Profound Autism

The University of Oxford and King’s College London (King’s) have joined the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, an international collaboration of sites working together to accelerate clinical trial readiness and therapeutic development for autism through a large-scale natural history and clinical endpoint study.

Similar stories

New $46M Grant Allows the University of Oxford and Boston Children’s Hospital to Lead Genetic Medicines Hub within ARIA Ecosystem

The University of Oxford and Boston Children’s Hospital, with collaboration from The Jackson Laboratory and N=1 Collaborative, have been selected to establish a new Genetic Medicines Hub, one of six research hubs within the Aligning Research to Impact Autism (ARIA) ecosystem.

Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.

University of Oxford and BIIE launch collaboration in translational immune engineering

Researchers from the Department of Paediatrics at the University of Oxford and the Botnar Institute of Immune Engineering (BIIE) came together in Oxford last week for the inaugural scientific meeting of the new Basel–Oxford Centre for Translational Immune Engineering for Child and Adolescent Health (CTIE). The CTIE is a new collaboration between the Department of Paediatrics and the BIIE in Basel, Switzerland, designed to accelerate the translation of advances in immune engineering into new diagnostics, vaccines, therapeutics and other approaches to prevent and treat disease. Its focus is on improving the health of children and adolescents in low- and middle-income countries.

Oxford-led newborn screening pilot expanded to include all babies in England

Every newborn baby in England will be screened for spinal muscular atrophy (SMA), following the expansion of a pioneering University of Oxford-led pilot that introduced the country’s first routine test for the condition.

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Oxford University and King’s College London Join IMPACT Network Study to Advance Understanding of Profound Autism

The University of Oxford and King’s College London (King’s) have joined the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, an international collaboration of sites working together to accelerate clinical trial readiness and therapeutic development for autism through a large-scale natural history and clinical endpoint study.